Analysts Downgrade Ventyx Biosciences Target Price to $14
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Source: Benzinga
- Rating Downgrade: Canaccord Genuity analyst Edward Nash downgraded Ventyx Biosciences Inc (NASDAQ:VTYX) from Buy to Hold and lowered the price target from $16 to $14, reflecting a cautious outlook on the company's future growth potential.
- Market Reaction: Ventyx Biosciences shares closed at $13.73 on Wednesday, below the new target price, indicating investor concerns about the company's prospects, which may affect short-term capital inflows.
- Industry Impact: This rating change could prompt follow-up actions from other analysts, further influencing Ventyx's market performance, especially amid increasing competition in the biotech sector.
- Investor Confidence: The downgrade may undermine investor confidence in Ventyx, particularly as the company seeks to attract more investment to support its R&D and market expansion efforts.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on VTYX
Wall Street analysts forecast VTYX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTYX is 13.38 USD with a low forecast of 9.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
0 Buy
8 Hold
0 Sell
Hold
Current: 13.970
Low
9.00
Averages
13.38
High
14.00
Current: 13.970
Low
9.00
Averages
13.38
High
14.00
About VTYX
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Investigation Announced
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating Nathan's Famous, Inc. (NASDAQ: NATH) regarding its sale to Smithfield Foods, Inc. for $102.00 per share, which may involve potential violations of federal securities laws impacting shareholder rights.
- Legal Rights Notification: Ventyx Biosciences, Inc. (NASDAQ: VTYX) is being sold to Eli Lilly for $14.00 per share, and Halper Sadeh LLC is urging shareholders to be aware of their legal rights and options to ensure transparency and fairness in the transaction.
- SkyWater Technology Sale: SkyWater Technology, Inc. (NASDAQ: SKYT) is selling for $15.00 in cash and $20.00 in IonQ common stock, with Halper Sadeh LLC potentially seeking increased consideration for shareholders to ensure fair compensation.
- No-Cost Legal Consultation: Halper Sadeh LLC offers free legal consultations, encouraging shareholders to reach out to discuss their legal rights and options, ensuring protection against potential securities fraud and corporate misconduct.
Continue Reading
Halper Sadeh Investigates Ventyx and Sun Country Transactions
- Legal Investigation Launched: Halper Sadeh LLC is investigating Ventyx Biosciences, Inc. (NASDAQ: VTYX) regarding its sale to Eli Lilly at $14.00 per share, which may involve potential violations of federal securities laws affecting shareholder rights.
- Shareholder Rights Protection: The firm is also examining the transaction between Sun Country Airlines Holdings, Inc. (NASDAQ: SNCY) and Allegiant Travel Company, which involves 0.1557 shares of Allegiant common stock and $4.10 in cash per Sun Country share, aiming to ensure fair compensation for shareholders.
- Legal Fee Arrangement: Halper Sadeh LLC will handle the case on a contingency fee basis, meaning shareholders will not incur out-of-pocket legal fees, thereby reducing financial burdens and encouraging more affected individuals to seek legal assistance.
- Global Investor Support: The firm is dedicated to providing legal support to investors worldwide, having successfully implemented corporate reforms and recovered millions for defrauded investors, showcasing its expertise in securities fraud and corporate misconduct.
Continue Reading